This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-21. Anything still debated is marked as such rather than presented as settled.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
== Education and early career == Cremer's father moved to a new position in Berlin and Cremer had trouble adjusting to the new Prussian school system. Cremer graduated high school in Berlin in 1921 and matriculated to the University of Berlin to study chemistry. At the University of Berlin, she attended lectures by Fritz Haber, Walther Nernst, Max Planck, Max von Laue, and Albert Einstein. Cremer received her Ph.D. magna cum laude six years later in 1927 under Max Bodenstein. Her dissertation was on the kinetics of the hydrogen-chlorine reaction. The paper was published under her name only because it concluded that the hydrogen-chlorine reaction was a chain reaction, which was still considered an extremely original concept for that time. Because of this paper and her work on kinetics, the future Nobel Laureate for the study of kinetics, Nikolay Semyonov invited her to Leningrad to work. She refused and remained in Germany to work at the Kaiser Wilhelm Institute for Physical Chemistry and Electrochemistry with Karl Friedrich Bonhoeffer on the quantum theoretical problems of photochemistry. Cremer studied the breakdown of alcohols using oxide catalysts on scholarship at the University of Freiburg with George de Hevesy for a brief time. Cremer returned to Berlin to work with Michael Polanyi at Haber's Institut, where they investigated the conversion of hydrogen and ortho-hydrogen in one spin state to para-hydrogen. She remained there until 1933 when the Nazi party came to power in Germany and the institute was dissolved for its reputation as anti-Nazi.
== Mission parameters == Mass: 3,570 kg (7,870 lb) Perigee (insertion): 165.8 km (103.0 mi; 89.5 nmi) Apogee (insertion): 293.7 km (182.5 mi; 158.6 nmi) Period: 88.94 min Inclination: 32.53° Perigee (last orbit): 150 km (93 mi; 81 nmi) Apogee (last orbit): 232.8 km (144.7 mi; 125.7 nmi)
Exercising regularly, as exercise increases cellular sugar uptake, which decreases excessive insulin release. Avoiding eating meals or snacks composed entirely of carbohydrates; simultaneously ingest fats and proteins, which have slower rates of absorption; Consistently choosing longer lasting, complex carbohydrates to prevent rapid blood-sugar dips in the event that one does consume a disproportionately large amount of carbohydrates with a meal; Monitoring any effects medication may have on symptoms. Low-carbohydrate diet and/or frequent small meals is the first treatment of this condition. The first important point is to add small meals at the middle of the morning and of the afternoon, when glycemia would start to decrease. If adequate composition of the meal is found, the fall in blood glucose is thus prevented. Patients should avoid rapidly absorbed sugars and thus avoid popular soft drinks rich in glucose or sucrose. They should also be cautious with drinks associating sugar and alcohol, mainly in the fasting state. As it is a short-term ailment, a sugar crash that was not caused by injecting too much insulin does not usually require medical intervention in most people. The most important factors to consider when addressing this issue are the composition and timing of foods. Acute (short-term) low blood sugar symptoms are best treated by consuming small amounts of sweet foods, so as to regain balance in the body's carbohydrate metabolism. Suggestions include sugary foods that are quickly digested, such as:
== Procedure == An aqueous sample is treated with an equal volume of 1% strong base (sodium or potassium hydroxide) followed by a few drops of aqueous copper(II) sulfate. If the solution turns purple, it contains protein. 5–160 mg/mL can be determined. Peptides with the correct length of at least 3 amino acids are necessary for a significant, measurable colour shift with these reagents.
==== Potential inequities resulting from digital agriculture ==== While digital technologies can facilitate market access and information flow, their benefits may not be evenly distributed, potentially exacerbating existing inequalities. Constraints on adoption can result in benefits accruing primarily to more powerful actors.
Sources: en.wikipedia.org
==== USP14/UBP6 ==== In contrast to Rpn11, USP14 and UCH37 are the DUBs that do not always associated with the proteasome and are not essential for ubiquitin dependent degradation. Instead, these DUBs are proposed to "edit" the ubiquitin code of a substrate that is already engaged with the proteasome. In cells, about 10-40% of the proteasomes were found to have USP14 associated. Ubp6/USP14 is a member of the Ubiquitin Specific Protease (USP) family, utilizing a catalytic cysteine to cleave ubiquitin. Along with the USP, Ubp6/USP14 contains a Ubiquitin-like protein (UBL) that binds the proteasome. Ubp6/USP14 is largely activated by the proteasome and exhibit a very low DUB activity alone. Once activated, USP14 was found to suppress proteasome function by its DUB activity and by inducing parallel pathways of proteasome conformational transitions, one of which turned out to directly prohibit substrate insertion into the AAA-ATPase, as first observed biochemically and later confirmed by time-resolved cryogenic electron microscopy. It appears that USP14 regulates proteasome function at multiple checkpoints by both catalytically competing with Rpn11 and allosterically reprogramming the AAA-ATPase states, which is rather unexpected for a DUB. These observations imply that the proteasome regulation may depend on its dynamic transitions of conformational states.
This convinced Macleod to divert the whole laboratory to insulin research and to bring in the biochemist James Collip to help with purifying the extract. The first human clinical trial was unsuccessful. Banting was insufficiently qualified to participate and felt sidelined. By the winter of 1922, he was certain that all Macleod's colleagues were conspiring against him. There was a reported physical altercation between Banting and Collip, as Banting saw Collip's breakthrough on alcohol purification as a threat, while Collip was reluctant to share the details. Collip threatened to leave because of the strained atmosphere but the encouragement of others who saw the potential of their research prevented escalation of the conflict. In January 1922, the team performed the first successful clinical trial, on 13-year-old Leonard Thompson, and it was soon followed by others. Although all the team members were listed as co-authors of their publications, Banting still felt overlooked, because Macleod took over the coordination of clinical trials and the acquisition of larger amounts of extract. Macleod's presentation at a meeting of the Association of American Physicians in Washington, D.C., on 3 May 1922 received a standing ovation, but Banting and Best refused to participate in protest. At that time, demonstrations of the method's efficiency drew huge public interest, because the effect on patients, especially children, who until then were bound to die, seemed almost miraculous. The pharmaceutical company Eli Lilly & Co.
=== Overview === Treatment is directed at managing the person's symptoms. For dry eyes, artificial tears; medications to reduce inflammation; punctal plugs or other surgery to shut the tear ducts may be tried. For a dry mouth, chewing gum (preferably sugar-free); sipping water; or a saliva substitute may be used. In those with joint or muscle pain, ibuprofen may be used. Medications that can cause dryness, such as antihistamines, may also be stopped. The most specific extant diagnostic test requires a lip biopsy.
Periostitis, also known as periostalgia, is a medical condition caused by inflammation of the periosteum, a layer of connective tissue that surrounds bone. The condition is most commonly chronic, and is marked by tenderness and swelling of the bone and pain.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.